Check Before You Invest : Thyrocare Technologies Ltd

Q: Which industry/sub-sector does Thyrocare Technologies Ltd belong to?

Thyrocare Technologies Ltd belongs to the Healthcare sector, operating specifically within the Hospital & Healthcare Services segment.

Q: Is Thyrocare Technologies Ltd a good quality company?

Thyrocare Technologies Ltd is a good quality company, based on a consistently good multi-year financial track record. This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q: Is Thyrocare Technologies Ltd undervalued or overvalued?

Thyrocare Technologies Ltd appears Somewhat overvalued, as its key valuation ratios are higher than their past averages. Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more. Valuation Ratios. Price to Earnings, Current: 45.85, Historic Median: 45.75. Price to Book, Current: 12.77, Historic Median: 8.56. Price to Sales, Current: 9.02, Historic Median: 7.35. EV to EBITDA, Current: 26.55, Historic Median: 23.89

Q: Is Thyrocare Technologies Ltd a good buy now?

Thyrocare Technologies Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Q: Revenue growth of Thyrocare Technologies Ltd?

Thyrocare Technologies Ltd revenue growth is 20.2% for FY-2025, which is above its 5-year CAGR of 9.62%, indicating faster growth.

Q: Gross Profit margin of Thyrocare Technologies Ltd?

Thyrocare Technologies Ltd Gross profit margin which is the profit after deduction of direct costs, is 29.4% for FY-2025, which is in line with its 5-year median of 29.4%, indicating stable margins.

Q: Operating Profit Margin of Thyrocare Technologies Ltd?

Thyrocare Technologies Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 27.8% for FY-2025, which is in line with its 5-year median of 27.8% indicating stable margins.

Q: Net Profit Margin of Thyrocare Technologies Ltd?

Thyrocare Technologies Ltd Net Profit Margin is 13.2% for FY-2025, is in line with its 5-year median of 13.2%, indicating stable margins. Profitability Metrics. Gross Profit Margin (%), Current: 29.4, Historic Median: 29.4. Operating Profit Margin (%), Current: 27.8, Historic Median: 27.8. Net Profit Margin (%), Current: 13.2, Historic Median: 13.2

Q: Return on Asset of Thyrocare Technologies Ltd?

Thyrocare Technologies Ltd Return on Asset is 13.82%, which is in line with its 5-year historical median of 13.82%, indicating stable asset utilization efficiency.

Q: Return on capital employed (ROCE) of Thyrocare Technologies Ltd?

Thyrocare Technologies Ltd Return on capital employed is 27.25% for FY-2025, which is in line with its 5-year historical median of 27.25%. The current ROCE is above its estimated weighted average cost of capital (WACC) of 14%, indicating value creation.

Check Before You Invest : Thyrocare Technologies Ltd

Snapshot

Q.1 Which industry/sub-sector does Thyrocare Technologies Ltd belong to?

Thyrocare Technologies Ltd belongs to the Healthcare sector, operating specifically within the Hospital & Healthcare Services segment.

Q.2 Is Thyrocare Technologies Ltd a good quality company?

Thyrocare Technologies Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q.3 Is Thyrocare Technologies Ltd undervalued or overvalued?

Thyrocare Technologies Ltd appears Somewhat overvalued, as its key valuation ratios are higher than their past averages.

Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more.

Valuation Ratios	Current	5-year Historic Median
Price to Earnings	45.85	45.75
Price to Book	12.77	8.56
Price to Sales	9.02	7.35
EV to EBITDA	26.55	23.89

Q.4 Is Thyrocare Technologies Ltd a good buy now?

Thyrocare Technologies Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

A: What are the trends in revenue and profit margins?

Q.1 Revenue growth of Thyrocare Technologies Ltd?

Thyrocare Technologies Ltd revenue growth is 20.2% for FY-2025, which is above its 5-year CAGR of 9.62%, indicating faster growth.

Q.2 Gross Profit margin of Thyrocare Technologies Ltd?

Thyrocare Technologies Ltd Gross profit margin which is the profit after deduction of direct costs, is 29.4% for FY-2025, which is in line with its 5-year median of 29.4%, indicating stable margins.

Q.3 Operating Profit Margin of Thyrocare Technologies Ltd?

Thyrocare Technologies Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 27.8% for FY-2025, which is in line with its 5-year median of 27.8% indicating stable margins.

Q.4 Net Profit Margin of Thyrocare Technologies Ltd?

Thyrocare Technologies Ltd Net Profit Margin is 13.2% for FY-2025, is in line with its 5-year median of 13.2%, indicating stable margins.

	Current Level	5-year Historic Median
Gross Profit Margin (%)	29.4	29.4
Operating Profit Margin (%)	27.8	27.8
Net Profit Margin (%)	13.2	13.2

B: Does the business utilize capital efficiently?

Q.5 Return on Asset of Thyrocare Technologies Ltd?

Thyrocare Technologies Ltd Return on Asset is 13.82%, which is in line with its 5-year historical median of 13.82%, indicating stable asset utilization efficiency.

Q.6 Return on capital employed (ROCE) of Thyrocare Technologies Ltd?

Thyrocare Technologies Ltd Return on capital employed is 27.25% for FY-2025, which is in line with its 5-year historical median of 27.25%. The current ROCE is above its estimated weighted average cost of capital (WACC) of 14%, indicating value creation.

Q.7 Return on Equity (ROE) of Thyrocare Technologies Ltd?

Thyrocare Technologies Ltd Return on equity is 17.04% for FY-2025, which is in line with its 5-year historical median of 17.04%, indicating the business is making similar use of its shareholders capital.

Q.8 Cash conversion cycle of Thyrocare Technologies Ltd?

Thyrocare Technologies Ltd Cash conversion cycle is 10 days, below its 5-year historical median of 31 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.

	Current Level	5-year Historic Median
Asset Turnover (x)	1.05	0.85
ROE (%)	17.04	17.04
ROCE (%)	27.25	27.25
Cash Conversion Cycle	10 days	31 days

C: How much debt does the business have and is it at a sustainable level?

Q.9 Debt to Equity ratio of Thyrocare Technologies Ltd?

Thyrocare Technologies Ltd Debt-to-Equity ratio is 0.00, which is lower the industry average of 0.20, indicating lower debt levels in the industry.

Q.10 Debt to cash flow from operations of Thyrocare Technologies Ltd?

Thyrocare Technologies Ltd Debt to cash flow from operations is 0, which is at a healthy level.

Ownership & governance

D: Promoter shareholding and pledge status of Thyrocare Technologies Ltd?

Q.1 Promoter shareholding and pledge status of Thyrocare Technologies Ltd?

Promoters hold 60.92% of the Thyrocare Technologies Ltd, with 100.00% of their stake pledged, indicating high pledge risk.

Peer comparison (industry-wise, mcap)

E: How does Thyrocare Technologies Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Thyrocare Technologies Ltd vs industry peers?

Thyrocare Technologies Ltd revenue CAGR is 9.62%, compared to the industry median CAGR of 1.38%, indicating faster growth and gaining its market share.

Profit Metrics

	Current Level	5-year Industry Median
Revenue Growth (%)	20.2	1.4
Gross Profit Growth (%)	41.3	18.5
Operating Profit Growth (%)	37.4	15.4
Net Profit Growth (%)	31.9	23.7

Operating Efficiency

	Current Level	5-year Industry Median
Asset Turnover (x)	1.05	0.73
ROE (%)	17.04	13.88
ROCE (%)	27.25	17.77
Cash Conversion Cycle (days)	10.24	1

Valuation & price assessment

Q.1 Stock return of Thyrocare Technologies Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 8.8% based on the current price.

	9Y	5Y	3Y	1Y
Share Price CAGR	8.8%	6.2%	44.7%	44.5%

Q.2 Valuation ratios of Thyrocare Technologies Ltd vs historical?

The current P/E ratio of 45.85 is in line with than its historical median of 45.75, indicating that the stock is trading near its historical average valuation.

Q.3 How do the current valuation ratios compare with 5-year historical median and industry numbers?

Valuation Ratios	Current	5-year Historic Median	5-year Industry Median
Price to Earnings	45.85	45.75	37.25
Price to Book	12.77	8.56	3.64
Price to Sales	9.02	7.35	4.21
EV to EBITDA	26.55	23.89	17.66

Check more companies

1. Global Health

2. Krishna Inst.Medi

3. Dr. Lal Pathlabs

4. Dr. Agarwals Health

5. RainbowChildrenS Med

6. Vijaya Diagnostic

7. Park Medi World

8. Metropolis Health.

9. Healthcare Global

10. Jupiter Life Line

Check trending companies

1. Solar Industries India Ltd.

2. IndusInd Bank Ltd.

3. 360 One Wam Ltd.

4. Pidilite Industries Ltd.

5. Kirloskar Oil Engines Ltd.

Check Before You Invest : Thyrocare Technologies Ltd

Snapshot

Performance Analysis

Ownership & governance

Peer comparison (industry-wise, mcap)

Profit Metrics

Operating Efficiency

Valuation & price assessment

Check more companies

Check trending companies

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.